Roche’s Xofluza reduces risk of catching flu by 86% in Phase 3 trial

September 2, 2019
Research and Development, Sales and Marketing Roche, Xofluza, flu, influenza, pharma

Roche has brought forward new Phase 3 data on Xofluza (baloxavir marboxil), proving the therapy’s efficacy in the preventative treatment …

Top Ten most popular articles on Pharmafile.com this week

August 30, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing pharma, top 10

Happy Friday! It’s time for another rundown of the top 10 most popular articles with Pharmafile.com readers this week.10. NICE …

Roche’s Tecentriq combo becomes first EU-approved immunotherapy for triple-negative breast cancer

August 30, 2019
Medical Communications, Sales and Marketing EMA, Europe, Roche, breast cancer, pharma, tecentriq

Roche has announced the approval of Tecentriq (atezolizumab), in combination with Celgene’s chemotherapy drug Abraxane (nab paclitaxel), by the European …

Genmab & Novartis’ ofatumumab tops Sanofi’s Aubagio in relapsing multiple sclerosis

August 30, 2019
Medical Communications, Research and Development Genmab, Novartis, multiple sclerosis, ofatumumab, pharma

Genmab and Novartis have revealed positive new data from two Phase 3 studies of its monthly subcutaneous formulation of ofatumumab …

AbbVie shuts down Rova-T development in first-line advanced small-cell lung cancer following another trial failure

August 30, 2019
Medical Communications, Research and Development AbbVie, pharma, rova-t, small-cell lung cancer

AbbVie has announced its intention to terminate development of Rova-T (rovalpituzumab tesirine) in the first-line maintenance of advanced small-cell lung …

Using advanced digital capabilities to unlock hard-to-see HCPs access

August 29, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing digital pharma, pharma, veeva

Pharmaceutical companies face a ‘digital imperative’ to engage with healthcare professionals through their channel preferences and ensure they are getting …

Celgene signs $1.5bn partnership with Immatics to fight cancer with engineered T-cell therapies

August 29, 2019
Research and Development Cancer, Celgene, immatics, immunotherapy, pharma

Celgene and biopharma firm Immatics Biotechnologies have announced that they have entered a partnership valued at a potential $1.5 billion …

FDA warns three Hepatitis C drugs may worsen liver function in some rare cases

August 29, 2019
Medical Communications, Research and Development AbbVie, FDA, Gilead, HCV, MSD, hepatitis C, public health

The FDA has warned that three Hepatitis C (HCV) drugs made by AbbVie, Gilead and MSD are worsening liver function …

AstraZeneca lupus drug makes comeback to meet main goal at Phase 3

August 29, 2019
Research and Development AstraZeneca, Lupus, anifrolumab, pharma

AstraZeneca has lifted the curtain on new Phase 3 data for anifrolumab, noting that the drug met its primary endpoint …

Oral contraceptive use as teenager linked to depression as an adult, study says

August 29, 2019
Research and Development MDD, depression, hormones, oral contraceptives, psychiatry, psychology

Women who have used oral contraceptives as teenagers are more likely to experience depression later in life, according to a …

Alexion’s Soliris scoops up expanded EU approval in neuromyelitis optica spectrum disorder

August 28, 2019
Research and Development, Sales and Marketing Alexion, FDA, US, pharma, soliris

Alexion has announced the expanded EU approval of Soliris (eculizumab) as a treatment for neuromyelitis optica spectrum disorder (NMOSD) in …

Sea snail chemical could be used as preventative treatment for bowel cancer, study shows

August 28, 2019
Research and Development Australia, Cancer, bowel cancer, pharma, research

A chemical produced by Australian sea snails is showing promise as a potential treatment for cancer, according to researchers from …

Johns Hopkins researchers to study psilocybin as a treatment for anorexia in Phase 1 trial

August 28, 2019
Research and Development Johns Hopkins, Magic mushrooms, anorexia, mushrooms, pharma, psilocybin

Scientists at Johns Hopkins University are exploring psilocybin as a potential treatment for chronic anorexia nervosa. Researchers at Johns Hopkins …

Over half of all US/EU regulator warnings issued to Indian and Chinese manufacturers, report finds

August 28, 2019
Manufacturing and Production, Research and Development China, India, MHRA, UK, manufacturing, pharma

Concerns have been raised concerning the integrity of the global supply chain after a report from The Pharmaceutical Journal revealed …

Sacklers could give up Purdue Pharma and settle 2,000 lawsuits for $10-12 billion, proposal says

August 28, 2019
Research and Development OxyContin, Purdue Pharma, Sackler family, opioid crisis, opioids, pharma

The Sackler family are offering to settle more than 2,000 opioid crisis lawsuits for between $10-12 billion, according to NBC. …

FibroGen rocked by unexpected death of CEO Thomas B Neff

August 27, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, fibrogen, pharma

In a saddening turn of events, San Francisco-based FibroGen has announced that Thomas B Neff, its Chief Executive Officer and …

NICE refuses GW Pharma’s cannabis-based Epidyolex for treatment-resistant epilepsy

August 27, 2019
Manufacturing and Production, Sales and Marketing Epidiolex, Epidyolex, GW Pharma, NICE, cannabidiol, cannabis, pharma

UK-based GW Pharma has suffered a setback in its home country after drug watchdog NICE chose not to recommend NHS …

The Royal College of Obstetricians and Gynaecologists (RCOG) call for action over shortages of hormone replacement therapy (HRT)

August 27, 2019
Manufacturing and Production HRT, UK, healthcare, pharma, shortages

The Royal College of Obstetricians and Gynaecologists (RCOG) have called for action from government and pharmaceutical companies to adress ongoing …

J&J must pay $572 million for fuelling opioid crisis in Oklahoma, judge says

August 27, 2019
Manufacturing and Production J&J, JJ, Johnson & Johnson, Oklahoma, opioid crisis, opioids, pharma

A judge in Oklahoma has said that Johnson & Johnson must pay $572 million for the part it played in …

The Gateway to Local Adoption Series

Latest content